Thymoma is a rare thoracic tumour, but remains one of the most common tumours originating in the mediastinum ([Thomas *et al*, 1999](#bib29){ref-type="other"}; [Giaccone, 2005](#bib8){ref-type="other"}; [Girard *et al*, 2009](#bib10){ref-type="other"}). Clinical behaviour tends to be indolent, but dissemination into the pleural space eventually occurs and sometimes distant metastasis arise ([Thomas *et al*, 1999](#bib29){ref-type="other"}). Thymoma is frequently associated with paraneoplastic syndromes such as myasthenia gravis or pure red cell aplasia ([Thomas *et al*, 1999](#bib29){ref-type="other"}; [Giaccone, 2005](#bib8){ref-type="other"}). No International Union Against Cancer (UICC) TNM classification is available, and the Masaoka classification has been widely used for clinical staging ([Masaoka *et al*, 1981](#bib22){ref-type="other"}; [Girard *et al*, 2009](#bib10){ref-type="other"}).

The majority of thymomas are discovered at a limited stage, representing Masaoka stage-I or II, and surgical resection is the treatment of choice for such cases ([Thomas *et al*, 1999](#bib29){ref-type="other"}; [Giaccone, 2005](#bib8){ref-type="other"}; [Girard *et al*, 2009](#bib10){ref-type="other"}). Even when the tumour invades neighbouring organs, as stage-III disease, surgical resection with postoperative radiotherapy is the preferred treatment when complete resection can be achieved ([Curran *et al*, 1988](#bib2){ref-type="other"}; [Urgesi *et al*, 1990](#bib32){ref-type="other"}; [Ogawa *et al*, 2002](#bib26){ref-type="other"}; [Strobel *et al*, 2004](#bib28){ref-type="other"}).

Systemic chemotherapy is usually used for stage-IVa (with pleural or pericardial dissemination) or stage-IVb disease (with lymphogenous or haematogenous metastases), but optimal management is less well established ([Thomas *et al*, 1999](#bib29){ref-type="other"}; [Girard *et al*, 2009](#bib10){ref-type="other"}). Several reports have described favourable outcomes in limited numbers of patients with stage-IVa disease treated using multimodal treatment including surgery ([Kim *et al*, 2004](#bib14){ref-type="other"}; [Yokoi *et al*, 2007](#bib33){ref-type="other"}).

Conversely, thymomas are generally reported to be chemotherapy-sensitive tumours, with response rates of 50--70% to combination chemotherapy ([Fornasiero *et al*, 1990](#bib4){ref-type="other"}; [Loehrer *et al*, 1994](#bib19){ref-type="other"}, [1997](#bib17){ref-type="other"}, [2001](#bib18){ref-type="other"}; [Giaccone *et al*, 1996](#bib9){ref-type="other"}; [Berruti *et al*, 1999](#bib1){ref-type="other"}; [Kim *et al*, 2004](#bib14){ref-type="other"}; [Lucchi *et al*, 2006](#bib21){ref-type="other"}; [Yokoi *et al*, 2007](#bib33){ref-type="other"}). Active agents include cisplatin (CDDP), vincristine (VCR), doxorubicin (ADM), etoposide (ETP), cyclophosphamide (CPM) and ifosfamide (IFX). Recent reports have shown marginal activity of pemetrexed ([Loehrer *et al*, 2006](#bib20){ref-type="other"}) and combined carboplatin and paclitaxel ([Lemma *et al*, 2008](#bib15){ref-type="other"}).

Dose-dense chemotherapy with the CODE combination (CDDP--VCR--ADM--ETP) and addition of granulocyte colony-stimulating factor (G-CSF) can be safely administered to patients with advanced lung cancer ([Murray *et al*, 1991](#bib25){ref-type="other"}; [Fukuoka *et al*, 1997](#bib6){ref-type="other"}). Theoretically, this approach might be suitable for chemosensitive tumours such as small-cell lung cancer and thymoma ([Goldie and Coldman, 1983](#bib11){ref-type="other"}, [1984](#bib12){ref-type="other"}; [Levin and Hryniuk, 1987](#bib16){ref-type="other"}; [Murray, 1987](#bib24){ref-type="other"}). Because some pilot data in Japan suggested that administration of 12 weeks of the CODE chemotherapy was barely feasible, subsequent Japanese trials used a modified schedule, which was shortened to 9 weeks ([Fukuoka *et al*, 1997](#bib6){ref-type="other"}; [Furuse *et al*, 1998](#bib7){ref-type="other"}).

In 1996, the Japan Clinical Oncology Group (JCOG) initiated two clinical trials for advanced thymoma: one aimed at evaluating the safety and efficacy of the CODE regimen in stage IV, disseminated thymoma (JCOG 9605), and the other aimed at evaluating the safety and efficacy of CODE combination chemotherapy followed by surgical resection and postoperative radiotherapy in initially unresectable stage-III thymoma (JCOG 9606). The primary endpoint in each study was progression-free survival (PFS). The results of JCOG 9605 are reported herein.

Patients and methods
====================

Eligibility criteria
--------------------

Patients with chemotherapy-naive, histologically documented thymoma at Masaoka stage IVa or IVb were eligible for entry into the study. Thymoma must have been confirmed histologically and thymic tumours with other histology, such as thymic carcinoma, carcinoid or lymphoma, were excluded. Each patient was required to fulfil the following criteria: age, 15--70 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS), 0--2; adequate organ function, that is, leukocyte count ⩾4000 *μ*l^−1^, platelet count ⩾10^5^ *μ*l^−1^, hemoglobin ⩾10.0 g dl^−1^, serum creatinine \<1.5 mg dl^−1^, creatinine clearance ⩾60 ml min^−1^, serum bilirubin \<1.5 mg dl^−1^, serum alanine transaminase and aspartate transaminase levels less than double the upper limit of the institutional normal range; and PaO~2~ ⩾70 mm Hg. Exclusion criteria included uncontrolled heart disease, uncontrolled diabetes or hypertension, pulmonary fibrosis or active pneumonitis as evidenced on chest radiography, infections necessitating systemic use of antibiotics, disease necessitating emergency radiotherapy such as superior vena cava obstruction syndrome, active concomitant malignancy and women who were pregnant or lactating. Also excluded were those patients with grave complications of thymoma, such as pure red cell aplasia or hypogammaglobulinemia. Myasthenia gravis was allowed and these patients were not excluded *per se*.

Patient eligibility was confirmed by the JCOG Data Center before patient registration. This study protocol was approved by the institutional review board at each participating centre and written informed consent was obtained from all patients prior to enrolment.

Treatment Plan
--------------

### Chemotherapy

Patients received the 9-week CODE combination chemotherapy as described below. Each chemotherapeutic agent was administered intravenously.

Week 1: CDDP 25 mg m^−2^ on day 1 with antiemetics and ample hydration; VCR (1 mg m^−2^) on day 1; ADM (40 mg m^−2^) on day 1 and ETP (80 mg m^−2^) on days 1--3.

Weeks 2, 4, 6 and 8: CDDP (25 mg m^−2^) on day 1 with antiemetics and ample hydration and VCR (1 mg m^−2^) on day 1.

Weeks 3, 5, 7 and 9: CDDP (25 mg m^−2^) on day 1 with antiemetics and ample hydration, ADM (40 mg m^−2^) on day 1 and ETP (80 mg m^−2^) on days 1--3.

Each week, G-CSF (filgrastim (50 *μ*g m^−2^ day^−1^) or lenograstim (2 *μ*g kg^−1^ day^−1^)) was administered by subcutaneous injection, except on days when chemotherapy was administered or when leukocyte count was ⩾10 000 *μ*l^−1^. Corticosteroid was used only as part of the antiemetic regimen, and the specific drug and dosage were not regulated by the protocol.

Dose and schedule modifications were performed as follows: when leukocyte count decreased to \<2,000 *μ*l^−1^ or platelet count decreased to \<50 000 *μ*l^−1^, chemotherapy was delayed by 1 week. If PS decreased to 3--4 or temperature reached ⩾38.0°C, therapy was likewise delayed for 1 week. No dose modification of chemotherapy drugs was adopted for toxicity.

Post-protocol therapy
---------------------

Surgery or radiotherapy was allowed after the completion of chemotherapy, at the discretion of the attending physician, even in the absence of apparent tumour regrowth. Conversely, additional chemotherapy without evidence of disease progression was not allowed.

Post-treatment after disease progression was not limited by the study protocol.

Patient evaluation and follow-up
--------------------------------

Before enrolment into the study, each patient underwent complete medical history taking and physical examination (including neurological check-up for signs of myasthenia gravis), determination of blood cell counts, serum biochemistry testing, arterial blood gas analysis, pulmonary function testing, electrocardiography, chest radiography, computed tomography (CT) of the chest, CT or ultrasonography of the upper abdomen, whole-brain CT or magnetic resonance imaging (MRI) and an isotope bone scan. Blood-cell counts, serum biochemistry testing and chest radiography were performed weekly during each course of chemotherapy.

The toxicity of chemotherapy was evaluated according to the JCOG Toxicity Criteria ([Tobinai *et al*, 1993](#bib30){ref-type="other"}), modified from version 1 of the National Cancer Institute Common Toxicity Criteria (NCI-CTC). Tumour responses were assessed radiographically according to the standard, two-dimensional WHO criteria ([Miller *et al*, 1981](#bib23){ref-type="other"}), and were classified as complete response (CR), partial response (PR), no change (NC), progressive disease (PD) or non-evaluable (NE). After completion of the protocol therapy, patients were followed up with periodic re-evaluation, including chest CT every 6 months for the first 2 years and annually thereafter.

Central review
--------------

Radiographic reviews for the eligibility of enrolled patients and clinical responses were performed at the time of the study group meeting, held every 3--4 months. The study coordinator (H Kunitoh) and a few selected investigators from the group reviewed the radiographic films. The clinical response data presented below were all confirmed by this central review. Reviews of pathological specimens were not performed, because of insufficient logistics of the study group at the time of the study activation in 1997.

Endpoints and statistical considerations
----------------------------------------

The primary endpoint in each study was PFS. Due the rarity of the tumour and the accrual reported in US trials, which required 10 years to register 26 patients with locally advanced (stage-III) disease ([Loehrer *et al*, 1997](#bib17){ref-type="other"}) and 9 years for 31 patients with disseminated (stage-IV) disease ([Loehrer *et al*, 1994](#bib19){ref-type="other"}), we presumed we would be capable of accruing 30 patients in the target accrual period of 4 years. The sample size was, therefore, not determined based on statistical calculations. The expected PFS for the JCOG 9605 study was 2 years, which would give a 95% confidence interval of 1.3--3.0 years with 30 cases.

The initial study design thus envisioned enrolment of 30 fully eligible cases over 3 years for the study, with a follow-up period of 2 years.

Secondary endpoints included toxicity and safety, objective tumour response to chemotherapy, pattern of relapse, and overall survival (OS).

Progression-free survival and OS were calculated from the date of enrolment and estimated using the Kaplan--Meier method. Progression-free survival was censored at the last date verifiable as progression-free, and OS was censored as of the date of last follow-up. During the accrual period, an interim analysis for futility was planned after half of the patients had been registered and followed for ⩾3 months. All analyses were performed using SAS software version 8.2/9.1 (SAS Institute, Cary, NC, USA).

Results
=======

Patient characteristics
-----------------------

A total of 30 patients from seven institutions were enrolled from July 1997 to March 2004. Three patients were later found ineligible due to wrong histology, with two cases of thymic carcinoma and one case of carcinoid. These mistakes occurred due to technical problems in the patient registry. Since the ineligible cases did receive the protocol therapy, all 30 patients were analysed for characteristics and toxicity. Twenty-seven eligible patients were analysed for clinical response and survival (PFS and OS). Patient characteristics are shown in [Table 1](#tbl1){ref-type="table"}.

Chemotherapy delivery and toxicity
----------------------------------

Nine weeks of chemotherapy were performed for 26 of the original 30 patients (87%). The other four patients included one patient receiving 7 weeks, two receiving 6 weeks and one receiving 3 weeks of therapy. Median duration of chemotherapy for the 26 patients who underwent the planned nine cycles was 10 weeks (range, 9--12 weeks).

[Table 2](#tbl2){ref-type="table"} summarises the major toxicities of chemotherapy, which were mainly haematological. Although 70% of patients experienced grade-IV neutropenia, this was generally transient and rarely complicated by infection/fever. Overall, toxicities were well tolerated and no deaths due to toxicity occurred.

Other and late complications
----------------------------

Four patients showed thymoma-related complications. One patient suffered from myasthenia gravis crisis occurring during chemotherapy, but subsequently recovered. Another patient showed newly diagnosed myasthenia gravis 2.5 years after completion of the protocol therapy, and thymectomy and resection of the residual tumour were performed. Two other cases had pure red cell aplasia occurring later in the clinical course with disease progression of the thymomas.

Clinical response to chemotherapy
---------------------------------

Clinical responses of the 27 eligible patients to chemotherapy were judged radiologically and confirmed by central review. Responses were as follows: CR, 0 patients; PR, 16 patients; NC, 10 patients and PD, 1 patient. Overall response rate was 59% (95% confidence interval, 39--78%).

Post-protocol therapy
---------------------

Post-protocol local therapy was administered to 18 of the 27 eligible patients (67%). Eight patients (all with stage-IVa disease) underwent surgical resection and 13 patients (nine with stage-IVa disease and four with stage-IVb disease) received thoracic radiotherapy, with three patients receiving both. Whether patients received local therapy after disease progression was not recorded on case report forms.

After disease progression, 16 of the 27 patients (59%) received additional chemotherapy. Post-protocol chemotherapy included platinum re-challenge, irinotecan, taxanes and investigational agents. Clinical response data to those therapies are not available.

PFS and OS
----------

Survival data were finally updated in March 2006, 2 years after accrual of the last patient. [Figure 1](#fig1){ref-type="fig"} shows PFS and OS curves of the 27 eligible patients. Median PFS was 0.79 years (95% confidence interval, 0.52--1.40 years) and PFS at 1 and 2 years was 37 and 15%, respectively. Median OS was 6.1 years and OS at 2 and 5 years was 89 and 65%, respectively.

Overall survival was longer for stage-IVa patients than for stage-IVb patients ([Figure 2](#fig2){ref-type="fig"}, median, 6.8 years and 3.5 years, respectively), but PFS was similar ([Figure 3](#fig3){ref-type="fig"}, median, 0.79 years for IVa patients and 0.78 years for IVb patients).

Pattern of relapse
------------------

As of the data cut-off, 26 of the 27 eligible patients had experienced tumour relapse. Sites of initial relapse comprised the primary site only in seven cases (27%), pleural or pericardial dissemination in seven cases (27%) and primary site and pleural/pericardial dissemination in nine cases (35%). Thus, 23 of the 26 patients with relapse initially showed regrowth of the primary and/or pleural or pericardial dissemination, with only three patients (12%) showing initial relapse at distant organs.

Discussion
==========

Few prospective trials of chemotherapy have been described for patients with advanced thymoma. Most prior studies have combined stage-III, localised disease and stage-IV, disseminated disease ([Table 3](#tbl3){ref-type="table"}). In addition, most have also included both thymoma and thymic carcinoma histology.

We have reported results for patients with stage-IV disease, for which systemic therapy should be the first choice. Among previous studies, only those from the ECOG separately reported results for stage-III and stage-IV patients ([Loehrer *et al*, 1994](#bib19){ref-type="other"}, [1997](#bib17){ref-type="other"}). The ECOG took 9 years to accrue 31 patients with stage-IV disease, including patients with thymic carcinoma ([Loehrer *et al*, 1994](#bib19){ref-type="other"}). We prospectively accrued patients with thymoma only and excluded thymic carcinoma, as thymoma and thymic carcinoma clearly differ in clinical presentation and prognosis, and trials involving these pathologies should, thus, be reported separately ([Eng *et al*, 2004](#bib3){ref-type="other"}; [Giaccone, 2005](#bib8){ref-type="other"}; [Lemma *et al*, 2008](#bib15){ref-type="other"}).

Trials of systemic chemotherapy for thymoma have reported response rates of 50--90%, so this tumour is generally considered sensitive to chemotherapy ([Thomas *et al*, 1999](#bib29){ref-type="other"}). Dose-dense chemotherapy such as the CODE four-drug combination has been argued to be theoretically suitable for the treatment of such chemosensitive tumours ([Murray, 1987](#bib24){ref-type="other"}).

Although our results showed that dose-dense CODE chemotherapy could be safely administered to thymoma patients, efficacy was not remarkable. The overall response rate was about 60%, no different from prior reports employing conventional-dose chemotherapy ([Table 3](#tbl3){ref-type="table"}). Progression-free survival was 9 months, falling far short of the expected 2 years. Although OS studies compared favourably with the corresponding ECOG trial ([Loehrer *et al*, 1994](#bib19){ref-type="other"}), attempting to reach a valid conclusion would be difficult due to the small sample sizes. In addition, OS could be greatly affected by post-study local therapy especially in patients with stage-IVa disease, as combined therapy trial including stage-IVa patients suggested ([Kim *et al*, 2004](#bib14){ref-type="other"}). In fact, this might be one reason why OS of stage-IVa patients was much longer than that of stage-IVb patients, whereas PFS was similar.

It could be argued that shortened CODE chemotherapy, used in Japan due to feasibility problem, led to inadequate results due to insufficient total dosages of chemotherapy drugs. However, another intensive chemotherapy, ETP--IFX--CDDP (VIP) supported by G-CSF, has also reported disappointingly low response rates and no better survival ([Loehrer *et al*, 2001](#bib18){ref-type="other"}). [Hanna *et al* (2001)](#bib13){ref-type="other"} reported five patients with prior chemotherapy treated with high-dose chemotherapy and stem cell support, but concluded that no superiority to conventional therapy was evident. Taken together with our results, intensification of chemotherapy does not appear sufficiently promising for treating advanced thymoma.

Many prior chemotherapy studies have included platinum and anthracyclines in their regimens. Non-anthracycline approaches contained regimens such as VIP ([Loehrer *et al*, 2001](#bib18){ref-type="other"}), ETP--CDDP ([Giaccone *et al*, 1996](#bib9){ref-type="other"}) and paclitaxel--carboplatin ([Lemma *et al*, 2008](#bib15){ref-type="other"}) tended to yield lower response rates of 32--56% as compared with regimens including anthracycline ([Table 3](#tbl3){ref-type="table"}). It might, thus, be suggested that both anthracycline and platinum should, thus, be included in thymoma chemotherapy, at least in current clinical practice.

Favourable results have recently been reported with multimodality therapy, including surgical resection of stage-IVa disease ([Kim *et al*, 2004](#bib14){ref-type="other"}; [Yokoi *et al*, 2007](#bib33){ref-type="other"}). In fact, about two-thirds of eligible patients in our trial received local therapy after chemotherapy, including surgery in eight patients. This could have affected the outcome of the patients, as discussed above. However, small sample size and patient selection preclude reaching any definitive conclusion. When and what local therapy, if any, would benefit patients with disseminated thymoma, remains yet to be established. Further studies are warranted.

The present study shows several additional limitations. One is that we did not perform a central review of histology, and, thus, could not provide WHO classifications of histology ([Okumura *et al*, 2002](#bib27){ref-type="other"}; [Travis *et al*, 2004](#bib31){ref-type="other"}). This makes comparisons with results from other reports difficult. Central pathology review and preferably tissue collection would be very important in future trials.

In addition, due to the shorter-than-expected PFS, the planned CT scan interval of every 6 months might not have accurately evaluated PFS ([Freidlin *et al*, 2007](#bib5){ref-type="other"}). Future trials might require more frequent scans.

In conclusion, we have reported that weekly dose-dense chemotherapy can be safely administered to patients with thymoma. However, efficacy seems similar to that in patients treated with conventional doses. More research on optimal systemic therapy and the role of local modalities would appear to be necessary.
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###### 

Patient characteristics

  **Item**                                       
  --------------------------------------- -------------
  *Sex*                                   
   Male/female                                16/14
                                                 
  *Age (years)*                           
   Median/range                            47.5/29--69
                                                 
  *ECOG performance status*               
   PS0/PS1/PS2                               11/18/1
                                                 
  *Masaoka stage*                         
   IVa/IVb                                    22/8
                                                 
  *Smoking history*                       
   No                                           9
   Yes (median pack--years)                  21 (22)
                                                 
  *Myasthenia gravis*                     
   No/yes                                     28/2
                                                 
  *Histology: thymoma and eligible*            27
   Lymphocyte predominance                     12
   Mixed cell                                   9
   Epithelioid cell                             4
   Clear cell                                   1
   Spindle cell                                 0
   Unclassified                                 1
                                                 
  *Histology: not thymoma (ineligible)*         3
   Carcinoma                                    2
   Carcinoid                                    1
   Lymphoma                                     0
                                                 
  *Prior therapy*                         
   None                                        26
   Surgery                                      2
   Surgery and radiation                        2

Abbreviations: ECOG=Eastern Cooperative Oncology Group; PS=performance status.

###### 

Toxicity of chemotherapy (*n*=30)

  **Toxicity**       **Grades 1/2**   **Grade 3**   **Grade 4**   **%Grade 3/4**
  ------------------ ---------------- ------------- ------------- ----------------
  Leukopenia         3/6              12            8             67
  Neutropenia        3/1              5             21            87
  Anemia             0/5              25            ND            83
  Thrombocytopenia   4/6              5             3             27
  ALT                9/0              0             0             0
  Creatinine         2/1              0             0             0
  PaO~2~             9/2              0             0             0
  Emesis             13/11            2             ND            7
  Diarrhoea          4/2              0             0             0
  Stomatitis         4/3              0             0             0
  Constipation       3/4              2             0             7
  Neuropathy         11/2             0             ND            0
  Infection          3/4              3             0             10

Abbreviations: ALT=alanine transaminase; ND=not defined (the JCOG toxicity criteria did not define grade IV in these toxicities).

###### 

Reports of combination chemotherapy for thymoma

  **Regimen**                                **Stage**  **Patients**^**a**^   **ORR**   **Reference**
  ----------------------------------------- ----------- --------------------- --------- ------------------------------------------------------
  *Anthracycline-containing regimens*                                                   
  ADOC (S)                                    III/IV    32                    91%       [Fornasiero *et al* (1990)](#bib4){ref-type="other"}
  PAC (G)                                       IV      30                    50%       [Loehrer *et al* (1994)](#bib19){ref-type="other"}
  PAC (G)                                       III     23                    70%       [Loehrer *et al* (1997)](#bib17){ref-type="other"}
  ADOC (S)                                    III/IV    16                    81%       [Berruti *et al* (1999)](#bib1){ref-type="other"}
  PAC (G)                                     III/IV    22                    77%       [Kim *et al* (2004)](#bib14){ref-type="other"}
  PAE (S)                                     III/IV    30                    73%       [Lucchi *et al* (2006)](#bib21){ref-type="other"}
  CAMP (S)                                    III/IV    14                    93%       [Yokoi *et al* (2007)](#bib33){ref-type="other"}
  CODE (G)                                      IV      27                    59%       Current study
                                                                                         
  *Non-anthracycline-containing regimens*                                               
  PE (G)                                      III/IV    16                    56%       [Giaccone *et al* (1996)](#bib9){ref-type="other"}
  VIP (G)                                     III/IV    20                    35%       [Loehrer *et al* (1997)](#bib17){ref-type="other"}
  CP (G)                                      III/IV    23                    35%       [Lemma *et al* (2008)](#bib15){ref-type="other"}

Abbreviations: ADOC=doxorubicin, cisplatin, vincristine, cyclophosphamide; CAMP=cisplatin, doxorubicin, methylpredonisolone; CODE=cisplatin, vincristine, doxorubicin, etoposide; CP=carboplatin, paclitaxel; G=prospective multicenter group trial; ORR=overall response rate; PAC=cisplatin, doxorubicin, cyclophosphamide; PAE=cisplatin, epidoxorubicin, etoposide; PE=cisplatin, etoposide; S=single-center experience; VIP=etoposide, ifosfamide, cisplatin.

Number of assessable patients.
